Belite Financial Statements From 2010 to 2026

BLTE Stock

USD 175.06 1.85 1.05%

Belite Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Belite Bio's valuation are provided below:

Market Capitalization

6.6 B

Earnings Share

(1.85)

There are over one hundred nineteen available fundamental signals for Belite Bio ADR, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Belite Bio's prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 1.8 B. The current year's Enterprise Value is expected to grow to about 1.8 B

Check Belite Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Belite Bio's main balance sheet or income statement drivers, such as Tax Provision of 5.5 K, Net Interest Income of 4.5 M or Interest Income of 4.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 12.49. Belite financial statements analysis is a perfect complement when working with Belite Bio Valuation or Volatility modules.

Build AI portfolio with Belite Stock

Check out the analysis of Belite Bio Correlation against competitors.

Belite Bio Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

183.7 M

175 M

56 M

Slightly volatile

Short and Long Term Debt Total

459.1 K

483.3 K

22.6 M

Slightly volatile

Other Current Liabilities

7 M

6.6 M

2.1 M

Slightly volatile

Total Current Liabilities

7.3 M

7 M

2.3 M

Slightly volatile

Property Plant And Equipment Net

836.9 K

1.1 M

377.1 K

Slightly volatile

Cash

45.1 M

36.4 M

31.9 M

Slightly volatile

Non Current Assets Total

6.1 M

5.8 M

1.5 M

Slightly volatile

Non Currrent Assets Other

185 K

92.7 K

88.5 K

Slightly volatile

Cash And Short Term Investments

175.3 M

166.9 M

53.9 M

Slightly volatile

Net Receivables

717.3 K

683.1 K

196.7 K

Slightly volatile

Common Stock Shares Outstanding

24.3 M

35.1 M

15.4 M

Slightly volatile

Liabilities And Stockholders Equity

183.7 M

175 M

56 M

Slightly volatile

Non Current Liabilities Total

223.2 K

234.9 K

22.6 M

Slightly volatile

Other Current Assets

1.6 M

1.5 M

369 K

Slightly volatile

Other Stockholder Equity

306.9 M

292.2 M

72.1 M

Slightly volatile

Total Liabilities

5.4 M

5.7 M

24.6 M

Slightly volatile

Property Plant And Equipment Gross

992.6 K

1.5 M

478 K

Slightly volatile

Total Current Assets

177.6 M

169.1 M

54.5 M

Slightly volatile

Capital Stock

2.4 K

3.5 K

1.6 K

Slightly volatile

Net Working Capital

170.3 M

162.2 M

52.2 M

Slightly volatile

Common Stock

2.4 K

3.5 K

1.6 K

Slightly volatile

Property Plant Equipment

77 K

108.1 K

62.8 K

Slightly volatile

Deferred Long Term Liabilities

652 K

733.5 K

800.6 K

Slightly volatile

Short Term Debt

343.5 K

248.4 K

390.1 K

Pretty Stable

Intangible Assets

2.7 M

4.6 M

875.3 K

Slightly volatile

Belite Bio Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Interest Income

4.5 M

4.3 M

751.8 K

Slightly volatile

Depreciation And Amortization

542.2 K

516.4 K

136.6 K

Slightly volatile

Interest Expense

19.1 K

23 K

19.9 K

Pretty Stable

Selling General Administrative

12.1 M

11.6 M

4.1 M

Slightly volatile

Other Operating Expenses

48.3 M

46 M

14.8 M

Slightly volatile

Research Development

36.2 M

34.4 M

10.7 M

Slightly volatile

Cost Of Revenue

542.2 K

516.4 K

136.6 K

Slightly volatile

Total Operating Expenses

48.3 M

46 M

14.8 M

Slightly volatile

Reconciled Depreciation

542.2 K

516.4 K

136.6 K

Slightly volatile

Selling And Marketing Expenses

319.2 K

359.1 K

392 K

Slightly volatile

Belite Bio Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

10.9 M

10.3 M

3.1 M

Slightly volatile

Begin Period Cash Flow

106.4 M

101.4 M

23.7 M

Slightly volatile

Depreciation

542.2 K

516.4 K

136.6 K

Slightly volatile

Capital Expenditures

154.4 K

173.7 K

72.4 K

Slightly volatile

End Period Cash Flow

45.1 M

36.4 M

31.9 M

Slightly volatile

Change To Netincome

1.6 M

1.8 M

1.4 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Capex To Depreciation

0.37

0.39

1.0972

Slightly volatile

Cash Per Share

2.19

4.28

2.8221

Pretty Stable

Income Quality

0.67

0.73

0.7838

Pretty Stable

Intangibles To Total Assets

0.0163

0.0236

0.0064

Slightly volatile

Current Ratio

17.04

21.88

24.0867

Slightly volatile

Capex Per Share

0.0052

0.0045

0.0037

Slightly volatile

Interest Debt Per Share

0.0199

0.021

2.3228

Slightly volatile

Debt To Assets

0.0039

0.0041

0.9039

Slightly volatile

Ebt Per Ebit

1.08

1.04

1.0007

Very volatile

Long Term Debt To Capitalization

1.27

1.71

1.454

Slightly volatile

Total Debt To Capitalization

0.004

0.0042

0.9453

Slightly volatile

Quick Ratio

17.04

21.88

24.0872

Slightly volatile

Net Income Per E B T

1.1

1.15

1.0149

Slightly volatile

Cash Ratio

5.72

6.02

21.2806

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

1.11

1.16

1.0218

Slightly volatile

Debt Ratio

0.0039

0.0041

0.9039

Slightly volatile

Belite Bio Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

1.8 B

1.7 B

651.4 M

Slightly volatile

Enterprise Value

1.8 B

1.7 B

652.1 M

Slightly volatile

Belite Fundamental Market Drivers

	Forward Price Earnings	222.2222
	Cash And Short Term Investments	145.1 M

Belite Upcoming Events

	29th of March 2024 Upcoming Quarterly Report	View
	8th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	29th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Belite Bio Financial Statements

Belite Bio stakeholders use historical fundamental indicators, such as Belite Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Although Belite Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Belite Bio's assets and liabilities are reflected in the revenues and expenses on Belite Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Belite Bio ADR. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Cost Of Revenue	516.4 K	542.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

When determining whether Belite Bio ADR is a strong investment it is important to analyze Belite Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Belite Bio's future performance. For an informed investment choice regarding Belite Stock, refer to the following important reports:

How To Invest In Belite

Details

Is Belite Stock a good investment?

Details

What is Belite Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Belite Bio Correlation against competitors.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Will Biotechnology sector continue expanding? Could Belite diversify its offerings? Factors like these will boost the valuation of Belite Bio. Projected growth potential of Belite fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Belite Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(1.85)

Return On Assets

(0.21)

Return On Equity

(0.32)

The market value of Belite Bio ADR is measured differently than its book value, which is the value of Belite that is recorded on the company's balance sheet. Investors also form their own opinion of Belite Bio's value that differs from its market value or its book value, called intrinsic value, which is Belite Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Belite Bio's market value can be influenced by many factors that don't directly affect Belite Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

It's important to distinguish between Belite Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Belite Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Belite Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Belite Financial Statements From 2010 to 2026

Belite Bio Balance Sheet

Belite Bio Income Statement

Belite Bio Cash Flow Statement

Financial Ratios

Belite Bio Valuation Data

Belite Fundamental Market Drivers

Belite Upcoming Events

About Belite Bio Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY